



Clinical Updates in Breast Cancer From San Antonio

Clinical Update 2 – Capivasertib for HR+/HER2– Advanced Breast Cancer: Results From the Phase 3 CAPItello-291 Trial

References

Tweet 3 References:

Howell S, Rugo H, Oliveira M, et al. (PS17-03) Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR positive/HER2-negative advanced breast cancer: exploratory analysis of PFS by AKT pathway gene from the Phase 3 CAPItello-291 trial. Presented at: SABCS; December 5–9 2023; San Antonio, TX. Accessed December 6, 2023.

<https://sabcs2023.eventscribe.net/fsPopup.asp?PresentationID=1328903&query=capitello&Mode=presentation>

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer (v5.2023). Updated December 5, 2023. Accessed December 7, 2023.

https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

TRUQAP™ (capivasertib). Prescribing information. AstraZeneca. Approved 2023. Revised November 2023.

<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197>

Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. *N Engl J Med*. 2023;388(22):2058-2070. doi:10.1056/NEJMoa2214131

Additional References:

Andre F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. *Ann Oncol*. 2021;32(2):208-217. doi:10.1016/j.annonc.2020.11.011

Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med*. 2012;366(6):520-529. doi:10.1056/NEJMoa1109653

Cerma K, Piacentini F, Moscetti L, et al. Targeting PI3K/AKT/mTOR pathway in breast cancer: from biology to clinical challenges. *Biomedicines*. 2023;11(1):109. doi:10.3390/biomedicines11010109



2L, second line
A/MBC, advanced or metastatic breast cancer
ABC, advanced breast cancer
AE, adverse event
AKT, protein kinase B
AR, androgen receptor
CI, confidence interval
DOR, duration of response
HER2–, human epidermal growth factor receptor 2 negative
HR, hazard ratio
HR+, hormone receptor positive
i, inhibitor
MBC, metastatic breast cancer
ORR, objective response rate
PFS, progression-free survival
PTEN, phosphatase and tensin homolog
w/, with
yo, year old